Election results boost tech, defense stocks
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Semtech beats analyst estimates for net income
Camarillo semiconductor supplier Semtech announced net income of $30.8 million, or 46 cents per diluted share, in its third quarter 2016 earnings release Nov. 30. Net income beat analyst estimates of 36 cents per share but net sales for the quarter of $137.2 million were just shy of estimates by Zacks Investment Research of $138.6 Read More →
9 tri-county companies on Deloitte Fast 500 list
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Central Coast startups work on stuff of science fiction
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Aerial Alchemy takes on challenge of managing drone data
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s Humira biosimilar delayed, Enbrel approved
Amgen’s Humira biosimilar Amjevita will be delayed at least through 2017 due to litigation by competitor AbbVie. The maker of Humira filed a patent infringement claim against Amgen on Aug. 4, alleging that the drug also violates the Biosimilar Price Competition and Innovation Act. Amgen was approved to market its biosimilar Sept. 23 by the Read More →
Resonant’s third quarter losses grow
Goleta-based Resonant reported a $4 million net loss, or a loss of 39 cents per diluted share, for the third quarter of 2016, up from a $2.9 million — or 40 cents per diluted share — loss in 2015. Revenues from contracts with four customers were $25,000 for the quarter ended Sept. 30. General and Read More →
